Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Shares Issued (2016 - 2025)

Protalix BioTherapeutics has reported Shares Issued over the past 11 years, most recently at $4.0 million for Q2 2025.

  • Quarterly results put Shares Issued at $4.0 million for Q2 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $6.8 million (changed N/A YoY), and the annual figure for FY2025 was $6.8 million, up 87.87%.
  • Shares Issued for Q2 2025 was $4.0 million at Protalix BioTherapeutics, up from $2.9 million in the prior quarter.
  • Over the last five years, Shares Issued for PLX hit a ceiling of $23.2 million in Q4 2023 and a floor of -$19.3 million in Q2 2023.
  • Median Shares Issued over the past 4 years was $4.0 million (2025), compared with a mean of $5.2 million.